Using 3D-MRE to assess liver disease and portal hypertension
Official title: Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study
Run by Shengjing Hospital · NCT05475015 · Data updated 2026-11-12
This study is testing if a new type of imaging called 3D-MRE can help doctors better understand and manage portal hypertension in patients with cirrhosis and advanced liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | August 16, 2022 |
| Main results expected | July 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT05475015 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old with confirmed cirrhosis or advanced chronic liver disease.
✕Probably not a fit
Patients with liver cancer, acute portal hypertension, or those who have undergone liver or spleen surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of three-dimensional magnetic resonance elastography (3D-MRE) as a non-invasive method to predict hepatic venous pressure gradient (HVPG) in patients with cirrhosis and advanced chronic liver disease. By establishing a risk stratification system, the study aims to improve tailored management for portal hypertension, a critical factor affecting patient outcomes. The research is particularly relevant in China, where liver disease is a significant public health concern, affecting over 400 million individuals. Participants will undergo 3D-MRE imaging within one month prior to HVPG measurement to evaluate the correlation between these two assessments.
Why it matters
Potential benefit: If successful, this approach could provide a safer, non-invasive method for monitoring and managing portal hypertension in patients with liver disease.
How similar studies have gone: While the use of 3D-MRE is a novel approach in this context, similar non-invasive imaging techniques have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior. Exclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.
Where it's running
-
Shengjing Hospital
Shenyang, Liaoning, China Recruiting
Study contacts
- Principal investigator: Yu Shi, Prof. — Shengjing Hospital
- Study coordinator: Yifei Huang, M.D.
- Email: huangyf1995@foxmail.com
- Phone: +86 158 0000 4518
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using carvedilol to prevent liver complications in patients with advanced chronic liver disease
This study is testing if the medication carvedilol can help prevent serious liver problems in people with advanced chronic liver disease and high blood pressure in the liver.
-
Surgery to improve liver function in cirrhosis patients
This study tests whether a specific surgery can help improve liver function in patients with cirrhosis who have an enlarged spleen.
-
Preventing liver complications after TIPS placement with rifaximin and lactulose
This study is testing if taking rifaximin and lactulose can help prevent brain problems in adults with liver cirrhosis after they have a procedure called TIPS.
-
Endohepatology-based reclassification of treatment indication in high-risk MASLD
This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.
-
Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS
A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.
-
Austrian PBC Registry
This registry follows adults with primary biliary cholangitis in Austrian centers to see how the disease develops over time and how biomarkers relate to complications and symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.